Trabectedin: An anticancer drug from the sea

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 16, 2009, Pages 2735-2743

  Ganjoo, Kristen N ^a   Patel, S R ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ET 743; Ovarian cancer; Soft tissue sarcoma; Trabectedin; Yondelis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; OMEGA CONOTOXIN MVIIA; TAXANE DERIVATIVE; TRABECTEDIN; TRANSCRIPTION FACTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC PAIN; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXCISION REPAIR; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEIOMYOBLASTOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; POSTMARKETING SURVEILLANCE; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SARCOMA; SEA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DIOXOLES; HUMANS; TETRAHYDROISOQUINOLINES;

EID: 72949084796     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903277236     Document Type: Review

References (39)

1. ADIS R&D profile. Trabectedin. Drugs RD 2003;4:75-81
2. Martinez EJ, Corey EJ. A new, more efficient, and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents. Org Lett 2000;2:993-996
3. Rinehart KL, Holt TG, Fregeau NL, et al. Ecteinascidins 729, 743, 745, 759A, and 770: potent antitumor agents from the caribbean tunicate ecteinascidia turbinate. J Org Chem 1990;55:4515-4516
4. Pommier Y, Kohlhagen G, Bailly C, et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate ecteinascidia turbinate. Biochemistry 1996;35:13303-13309
5. ADIS R&D profile. Trabectedin. Drugs RD 2006;7:317-328
6. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-987
7. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetics study of yondelis (Ecteinascidin-743: ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003;39:1842-1851
8. Forouzesh B, Hidalgo M, Chu Q, et al. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin Cancer Res 2009;15:3591-3599
9. Taamma A, Misset J, Riofrio M, et al. Phase I and pharmacokinetic study of Ecteinascidin-743, a new marine compound, administered as a 24 hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265
10. Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variable and toxicity. Cancer Chemother Pharmacol 2002;50:309-319
11. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteiniscidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-242
12. Beumer JH, Schellens JHM, Beijnen JH. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacol Res 2005;51:391-398
13. Villalona-Calero MA, Eckhardt G, Weiss G, et al. A phase I and pharmacokinetic study of Ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8:75-85
14. Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009;45:1153-1161
15. Blay JY, von Mehren M, Samuels BL, et al. Phase I combinatioin study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008;14:6656-6662
16. Von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19:1802-1809
17. Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumors. Eur J Cancer 2009; doi:10.1016/j.ejca.2009.04.002
18. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008;63:181-188
19. Le Cesne A, Blay JY, Van Oosterom A, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 2005;23:576-584
20. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (Ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8:595-602
21. Patel SR, Burgess MA, Plager C, et al. Myxoid liposarcoma: experience with chemotherapy. Cancer 1994;74:1265-1269
22. Gronchi A, Le Cesne A, Bui NB, et al. A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). J Clin Oncol 2009;27(Suppl 15):542
23. Grosso F, Forni C, Frapolli R, et al. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. J Clin Oncol 2007;25(Suppl 18):100
24. Schoffski P, Casali PG, Taron M, et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006;24(Suppl 18):9522
25. Morgan JA, Le Cesne A, Chawla S, et al. Randomized phase II study of trabectedin in patients with liposarcoma and Leiomyosarcoma (L-sarcoma) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol 2007;25(Suppl 18):10060
26. Demetri GD, Schuetze S, Blay J, et al. Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma oe leiomyosarcoma after failure of prior anthracycline and ifosfamide. J Clin Oncol 2009;27(Suppl 15):10509
27. Krasner CN, McMeekin DS, Chan S, et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-1624
28. Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fail. J Clin Oncol 2005;23:1867-1874
29. Del Campo J, Roszak A, Ciuleanu T, et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 2006;24(Suppl 18):5031
30. Zelek L, Yovine A, Brain E, et al. A phase II study of yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006;94:1610-1614
31. Gurtler JS, Goldstein L, Delprete S, et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 2005;23(Suppl 16):625
32. Michaelson MD, Gilligan T, Oh W, et al. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 2005;23(Suppl 16):4517
33. Monk B, Herzog T, Kaye S, et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Eur J Cancer 2008;16:ESMO-LBA4
34. Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100:339-348
35. Manara MC, Perdichizzi S, Serra M, et al. The molecular mechanisms responsible for resistance to ET-743 (trabectedin; yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005;27:1605-1616
36. Ryan DP, Puchalski T, Supko JG, et al. A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002;7:531-538
37. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J Clin Oncol 2001;19:1248-1255
38. Yovine A, Riofrio M, Blay JY, et al. Phase II study of Ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899
39. Huygh G, Clement PM, Dumez H, et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma 2006; doi: 10.1155/SRCM/2006/562